{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:05:18Z","timestamp":1788455118069,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jconrel.2024.07.062","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:35:45Z","timestamp":1724459745000},"page":"369-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies"],"prefix":"10.1016","volume":"374","author":[{"given":"Ryan P.","family":"Nolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Maneval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"LaBarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie A.","family":"Printz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J."},{"issue":"5","key":"10.1016\/j.jconrel.2024.07.062_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/NAN.0b013e31824d2271","article-title":"Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs","volume":"35","author":"Dychter","year":"2012","journal-title":"J. Infus. Nurs."},{"issue":"2","key":"10.1016\/j.jconrel.2024.07.062_bb0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0091270012436560","article-title":"Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I\/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer","volume":"53","author":"Wynne","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.062_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"De Cock","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jconrel.2024.07.062_bb0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.07.062_bb0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fonc.2015.00192","article-title":"Breaching the castle walls: hyaluronan depletion as a therapeutic approach to cancer therapy","volume":"5","author":"Shepard","year":"2015","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.062_bb0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv."},{"issue":"7","key":"10.1016\/j.jconrel.2024.07.062_bb0045","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1053\/j.gastro.2016.03.040","article-title":"Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma","volume":"150","author":"DuFort","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0050","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1007\/BF00586226","article-title":"The ultrastructure and physical-chemical properties of interstitial connective tissue","author":"Laurent","year":"1972","journal-title":"Pflugers Arch."},{"issue":"2","key":"10.1016\/j.jconrel.2024.07.062_bb0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","article-title":"A recombinant human enzyme for enhanced interstitial transport of therapeutics","volume":"114","author":"Bookbinder","year":"2006","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.062_bb0060","first-page":"9","article-title":"Recombinant human hyaluronidase PH20 (rHuPH20) facilitated subcutaneous delivery of proteins in nonclinical models","volume":"30","author":"Kang","year":"2013","journal-title":"Controll. Release Newsl."},{"issue":"4741","key":"10.1016\/j.jconrel.2024.07.062_bb0065","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/bmj.2.4741.1178","article-title":"Reconstitution of the dermal barrier to dye spread after hyaluronidase injection","volume":"2","author":"Bywaters","year":"1951","journal-title":"Br. Med. J."},{"issue":"11","key":"10.1016\/j.jconrel.2024.07.062_bb0070","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1080\/17425247.2021.1981286","article-title":"Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery","volume":"18","author":"Knowles","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"issue":"4741","key":"10.1016\/j.jconrel.2024.07.062_bb0075","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/bmj.2.4741.1173","article-title":"Hyaluronidase skin spreading effect; an analysis of repeated measurements","volume":"2","author":"Holborow","year":"1951","journal-title":"Br. Med. J."},{"issue":"7","key":"10.1016\/j.jconrel.2024.07.062_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254765","article-title":"Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: a locally acting and transiently active permeation enhancer","volume":"16","author":"Kang","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.062_bb0085","doi-asserted-by":"crossref","first-page":"2252999","DOI":"10.1080\/10717544.2023.2252999","article-title":"Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model","volume":"30","author":"Connor","year":"2023","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.062_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12249-020-01880-0","article-title":"Subcutaneous injection performance in Yucatan miniature pigs with and without human hyaluronidase and auto-injector tolerability in humans","volume":"22","author":"Shi","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"10.1016\/j.jconrel.2024.07.062_bb0095","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jcph.1362","article-title":"Development of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab: results from the phase Ib dose-finding study","volume":"59","author":"Kirschbrown","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.07.062_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2020.100604","article-title":"A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human hyaluronidase PH20 administered intravenously in healthy volunteers","volume":"93","author":"Printz","year":"2020","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.jconrel.2024.07.062_bb0105","author":"Halozyme Therapeutics Inc"},{"issue":"8","key":"10.1016\/j.jconrel.2024.07.062_bb0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2217\/imt-2021-0336","article-title":"Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study","volume":"14","author":"Borte","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0115","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0120","author":"US Food and Drug Administration"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0125","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0130","series-title":"PHESGO\u00ae [package insert]. South San Francisco, CA","author":"Genentech Inc","year":"2020"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0135","author":"Genentech Inc"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0140","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0145","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0150","author":"Janssen Biotech Inc"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0155","author":"UK Electronic Medicines Compendium"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0160","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0165","author":"Food and Drug Administration"},{"issue":"12","key":"10.1016\/j.jconrel.2024.07.062_bb0170","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/10245330400026154","article-title":"Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure","volume":"10","author":"Lim","year":"2005","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02990843","article-title":"Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy","volume":"13","author":"Ragnhammar","year":"1996","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.062_bb0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1208\/s12248-022-00757-3","article-title":"Risk factors, hyaluronidase expression, and clinical immunogenicity of recombinant human hyaluronidase PH20, an enzyme enabling subcutaneous drug administration","volume":"24","author":"Printz","year":"2022","journal-title":"AAPS J."},{"issue":"5","key":"10.1016\/j.jconrel.2024.07.062_bb0190","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1208\/s12248-015-9782-0","article-title":"Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration","volume":"17","author":"Rosengren","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2024.07.062_bb0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7827-1-54","article-title":"SPAM1 (PH-20) protein and mRNA expression in the epididymides of humans and macaques: utilizing laser microdissection\/RT-PCR","volume":"1","author":"Evans","year":"2003","journal-title":"Reprod. Biol. Endocrinol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.062_bb0200","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/j.1939-4640.2000.tb03412.x","article-title":"Mouse Spam1 (PH-20): evidence for its expression in the epididymis and for a new category of spermatogenic-expressed genes","volume":"21","author":"Deng","year":"2000","journal-title":"J. Androl."},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.062_bb0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40259-018-0260-y","article-title":"Recombinant human PH20: baseline analysis of the reactive antibody prevalence in the general population using healthy subjects","volume":"32","author":"Rosengren","year":"2018","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0210","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/rep.1.00016","article-title":"Assessment of contraceptive vaccines based on recombinant mouse sperm protein PH20","volume":"127","author":"Hardy","year":"2004","journal-title":"Reproduction"},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0215","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1034\/j.1600-0897.2002.1o056.x","article-title":"Restricted entry of IgG into male and female rabbit reproductive ducts following immunization with recombinant rabbit PH-20","volume":"47","author":"Pomering","year":"2002","journal-title":"Am. J. Reprod. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.062_bb0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-0378(79)90030-5","article-title":"The effect on fertility of immunizing female sheep with ram sperm acrosin and hyaluronidase","volume":"1","author":"Morton","year":"1979","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.jconrel.2024.07.062_bb0225","series-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council","year":"1996"},{"issue":"6","key":"10.1016\/j.jconrel.2024.07.062_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157003","article-title":"Biologic data of Cynomolgus monkeys maintained under laboratory conditions","volume":"11","author":"Rosso","year":"2016","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.jconrel.2024.07.062_bb0235","doi-asserted-by":"crossref","first-page":"10071","DOI":"10.1073\/pnas.90.21.10071","article-title":"Molecular cloning of the human and monkey sperm surface protein PH-20","volume":"90","author":"Lin","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.07.062_bb0240","author":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)"},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0245","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10408444.2011.653487","article-title":"The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy","volume":"42","author":"DeSesso","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.jconrel.2024.07.062_bb0250","author":"U.S. Food and Drug Administration"},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.062_bb0255","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/01926230252824725","article-title":"Recognition of adverse and nonadverse effects in toxicity studies","volume":"30","author":"Lewis","year":"2002","journal-title":"Toxicol. Pathol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0260","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cne.901800305","article-title":"Properties of the enteric nervous system: limitation of access of intravascular macromolecules to the myenteric plexus and muscularis externa","volume":"180","author":"Gershon","year":"1978","journal-title":"J. Comp. Neurol."},{"issue":"5","key":"10.1016\/j.jconrel.2024.07.062_bb0265","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1095\/biolreprod.110.087452","article-title":"The blood-testis and blood-epididymis barriers are more than just their tight junctions","volume":"84","author":"Mital","year":"2011","journal-title":"Biol. Reprod."},{"issue":"1","key":"10.1016\/j.jconrel.2024.07.062_bb0270","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1124\/pr.110.002790","article-title":"The blood-testis barrier and its implications for male contraception","volume":"64","author":"Cheng","year":"2012","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2024.07.062_bb0275","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.RES.74.2.244","article-title":"Hyaluronate degradation affects ventricular function of the early postlooped embryonic rat heart in situ","volume":"74","author":"Baldwin","year":"1994","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2024.07.062_bb0280","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI10272","article-title":"Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme","volume":"106","author":"Camenisch","year":"2000","journal-title":"J. Clin. Invest."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:42:50Z","timestamp":1741257770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924005200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":56,"alternative-id":["S0168365924005200"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.062","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}